Access to the GLP-1 will be streamlined, and starting July 1, will result in a limited-time $299 price for eligible self-pay patients.
Novo Nordisk is growing coverage of its Wegovy (semaglutide) injection 2.4 mg in the form of a new deal with WeightWatchers that takes effect July 1.1 CenterWell Pharmacy will be the dispensing pharmacy responsible for fulfilling and delivering the GLP-1 on behalf of NovoCare Pharmacy.
The move represents a concerted effort by Novo to expand patient access to the product. By offering Wegovy access through its integrated support system, WeightWatchers hopes to offer patients not only a more efficient experience, but a simpler way to access the medication.
"We understand that how people choose to receive care is changing, and in response to that, we are collaborating with WeightWatchers to deliver more accessible care to those living with chronic obesity," commented Dave Moore, Novo Nordisk’s executive vice president of US operations. "WeightWatchers has spent over six decades building a science-backed approach to weight management, and we see strong synergy in our shared commitment to improving long-term health outcomes. We have also been very encouraged with our existing Ro and LifeMD collaborations. We will continue to pursue and build on agreements with companies that share our values and refine initiatives that help improve access to our FDA-approved medicines for patients."
Further, from July 1 through July 31, Novo Nordisk will be promoting a new cash-offer price of $299 available for Wegovy. Self-paying patients who are new to the Wegovy savings offer or those who have not previously filled a prescription through NovoCare Pharmacy are eligible for this $299 introductory price.
There is currently a $199 Wegovy cash-offer patient price that expires today (June 30). For those patients who had redeemed this savings offer between the dates of May 22 and June 30, they would also qualify for the $299 price on one fill between the aforementioned July 1-July 31 timeframe. The monthly fee for self-paying patients after this date will increase to $499.
Since semaglutide is FDA-approved at all dose levels and widely available in the United States, Novo Nordisk is reminding the public that making or selling compounded or imitation versions is illegal under US compounding laws, except in rare cases.
One recent example of an illegal instance occurred just last week, when Novo Nordisk terminated its partnership with Hims & Hers2 over claims that the company had been selling counterfeit versions of Wegovy and had “failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of "personalization" and are disseminating deceptive marketing that put patient safety at risk.”
Novo has been collaborating with telehealth companies to encourage additional access to the GLP-1. Although Hims & Hers’ relationship with Novo may have ended, the company has an existing partnership3 with Eli Lilly, in which they are permitted to sell Zepbound, a GLP-1 approved by the FDA for weight loss, and Mounjaro, which is not approved for weight loss but for the treatment of type 2 diabetes. Both the Zepbound and Mounjaro injections will run customers $1,899 a month on the Hims & Hers website.
However, Lilly’s LillyDirect platformthat was launched back in January 2024—which is known for providing resources for disease management, featuring access to independent healthcare providers, support, and direct home delivery of certain Lilly medicines through third-party pharmacy dispensing services—offers different prices.
At the time of that announcement, Eli Lilly clarified that “has no affiliation with Hims & Hers. Zepbound (tirzepatide) can be prescribed by any licensed healthcare professional.”
References
1. Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy and prioritize patient safety. PR Newswire. June 26, 2025. Accessed June 30, 2025. https://www.prnewswire.com/news-releases/novo-nordisk-continues-efforts-to-support-patient-access-to-authentic-fda-approved-wegovy-and-prioritize-patient-safety-302492419.html
2. Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing. PR Newswire. June 23, 2025. Accessed June 30, 2025. https://www.prnewswire.com/news-releases/novo-nordisk-terminates-collaboration-with-hims--hers-health-inc-due-to-concerns-about-their-illegal-mass-compounding-and-deceptive-marketing-302488189.html
3. Saraceno N. Hims & Hers Begins Selling Zepbound. Pharmaceutical Commerce. April 2, 2025. Accessed June 30, 2025. https://www.pharmaceuticalcommerce.com/view/hims-hers-begins-selling-zepbound
